STGD1

Clinical trials for STGD1 explained in plain language.

Never miss a new study

Get alerted when new STGD1 trials appear

Sign up with your email to follow new studies for STGD1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet finished but already full! 1

New hope for rare eye disease: drug trial targets vision loss

Disease control Ongoing

This study tests a drug called tinlarebant in 60 people with Stargardt disease, a genetic condition that causes vision loss. The goal is to see if the drug can slow damage to the retina and preserve eyesight. Participants take the drug or a placebo, and researchers measure change…

Matched conditions: STGD1

Phase: PHASE2, PHASE3 • Sponsor: Belite Bio, Inc • Aim: Disease control

Last updated Jun 27, 2026 11:00 UTC

STGD1

Get alerted when new STGD1 trials appear

New hope for rare eye disease: drug trial targets vision loss